The compositions or treatments of the present invention can further comprise low-density lipoprotein (LDL) receptor activators such as HOE-402, an imidazolidinyl-pyrimidine derivative that directly stimulates LDL receptor activity.
A total daily dosage of LDL receptor activator (s) can range from about 1 to about 1000 mg/day in single or 2-4 divided doses.